E Fund Management’s Ligand Pharmaceuticals LGND Stock Holding History

E Fund Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,012	Closed	-$216K	–	345
2022 Q3	$216K	Sell	4,012 -1,151	-22%	-$67.7K	0.02%	292
2022 Q2	$287K	Buy	5,163 +1,317	+34%	+$74.7K	0.03%	241
2022 Q1	$270K	Buy	+3,846	New	+$279K	0.01%	235

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

E Fund Management's LGND Position: Q4 2022 in Review

E Fund Management sold out of Ligand Pharmaceuticals (LGND) in Q4 2022, closing a stake of 4,012 shares — an estimated $216K sold.

E Fund Management first reported a position in LGND in Q1 2022 and held it in 3 quarters. The position peaked at $287K in Q2 2022. 198 funds tracked by Wall St. Rank hold LGND as of Q4 2022.

E Fund Management reported no remaining Ligand Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
E Fund Management sold 4,012 Ligand Pharmaceuticals shares in Q4 2022, an estimated $216K.
E Fund Management first reported a position in Ligand Pharmaceuticals in Q1 2022 and held it in 3 quarters.
E Fund Management's Ligand Pharmaceuticals position peaked at $287K in Q2 2022.
198 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2022.

Based on E Fund Management's 13F filing for Q4 2022, filed 14 Feb 2023.